Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

Yoko Ishida, Kiriko Terasako, Kumi Oshima, Kana Sakamoto, Masahiro Ashizawa, Miki Sato, Misato Kikuchi, Shun Ichi Kimura, Hideki Nakasone, Shinya Okuda, Shinichi Kako, Rie Yamazaki, Junji Nishida, Yoshinobu Kanda

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Although allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), the prognosis of patients who relapse after allogeneic HSCT has been extremely poor. Dasatinib, a second-generation tyrosine kinase inhibitor, is a promising agent for the treatment of Ph-ALL. We report on a Ph-ALL patient who relapsed early after the first allogeneic HSCT, but achieved complete molecular remission with dasatinib alone. She remains in molecular remission 12 months after the second allogeneic HSCT. Dasatinib was generally well tolerated, but she developed myalgia, nausea and positive cytomegalovirus antigenemia. In addition, sudden-onset bloody diarrhea was observed 10 days after the second HSCT, which was possibly associated with the use of dasatinib in addition to the effect of the conditioning regimen and graft-versus-host disease. In conclusion, dasatinib is an effective agent for Ph-ALL with a poor prognosis, but may be associated with specific adverse events including opportunistic infection and gastrointestinal bleeding.

Original languageEnglish
Pages (from-to)542-546
Number of pages5
JournalInternational Journal of Hematology
Volume92
Issue number3
DOIs
Publication statusPublished - 2010 Oct 1
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transplantation
Recurrence
Myalgia
Opportunistic Infections
Graft vs Host Disease
Cytomegalovirus
Protein-Tyrosine Kinases
Nausea
Diarrhea
Dasatinib
Hemorrhage
Therapeutics

Keywords

  • Dasatinib
  • Hematopoietic stem cell transplantation
  • Philadelphia chromosome-positive acute lymphoblastic leukemia

ASJC Scopus subject areas

  • Hematology

Cite this

Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation. / Ishida, Yoko; Terasako, Kiriko; Oshima, Kumi; Sakamoto, Kana; Ashizawa, Masahiro; Sato, Miki; Kikuchi, Misato; Kimura, Shun Ichi; Nakasone, Hideki; Okuda, Shinya; Kako, Shinichi; Yamazaki, Rie; Nishida, Junji; Kanda, Yoshinobu.

In: International Journal of Hematology, Vol. 92, No. 3, 01.10.2010, p. 542-546.

Research output: Contribution to journalArticle

Ishida, Y, Terasako, K, Oshima, K, Sakamoto, K, Ashizawa, M, Sato, M, Kikuchi, M, Kimura, SI, Nakasone, H, Okuda, S, Kako, S, Yamazaki, R, Nishida, J & Kanda, Y 2010, 'Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation', International Journal of Hematology, vol. 92, no. 3, pp. 542-546. https://doi.org/10.1007/s12185-010-0678-6
Ishida, Yoko ; Terasako, Kiriko ; Oshima, Kumi ; Sakamoto, Kana ; Ashizawa, Masahiro ; Sato, Miki ; Kikuchi, Misato ; Kimura, Shun Ichi ; Nakasone, Hideki ; Okuda, Shinya ; Kako, Shinichi ; Yamazaki, Rie ; Nishida, Junji ; Kanda, Yoshinobu. / Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation. In: International Journal of Hematology. 2010 ; Vol. 92, No. 3. pp. 542-546.
@article{6f77fb06b3794e5dbb57e2703dd7f317,
title = "Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation",
abstract = "Although allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), the prognosis of patients who relapse after allogeneic HSCT has been extremely poor. Dasatinib, a second-generation tyrosine kinase inhibitor, is a promising agent for the treatment of Ph-ALL. We report on a Ph-ALL patient who relapsed early after the first allogeneic HSCT, but achieved complete molecular remission with dasatinib alone. She remains in molecular remission 12 months after the second allogeneic HSCT. Dasatinib was generally well tolerated, but she developed myalgia, nausea and positive cytomegalovirus antigenemia. In addition, sudden-onset bloody diarrhea was observed 10 days after the second HSCT, which was possibly associated with the use of dasatinib in addition to the effect of the conditioning regimen and graft-versus-host disease. In conclusion, dasatinib is an effective agent for Ph-ALL with a poor prognosis, but may be associated with specific adverse events including opportunistic infection and gastrointestinal bleeding.",
keywords = "Dasatinib, Hematopoietic stem cell transplantation, Philadelphia chromosome-positive acute lymphoblastic leukemia",
author = "Yoko Ishida and Kiriko Terasako and Kumi Oshima and Kana Sakamoto and Masahiro Ashizawa and Miki Sato and Misato Kikuchi and Kimura, {Shun Ichi} and Hideki Nakasone and Shinya Okuda and Shinichi Kako and Rie Yamazaki and Junji Nishida and Yoshinobu Kanda",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s12185-010-0678-6",
language = "English",
volume = "92",
pages = "542--546",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

AU - Ishida, Yoko

AU - Terasako, Kiriko

AU - Oshima, Kumi

AU - Sakamoto, Kana

AU - Ashizawa, Masahiro

AU - Sato, Miki

AU - Kikuchi, Misato

AU - Kimura, Shun Ichi

AU - Nakasone, Hideki

AU - Okuda, Shinya

AU - Kako, Shinichi

AU - Yamazaki, Rie

AU - Nishida, Junji

AU - Kanda, Yoshinobu

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Although allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), the prognosis of patients who relapse after allogeneic HSCT has been extremely poor. Dasatinib, a second-generation tyrosine kinase inhibitor, is a promising agent for the treatment of Ph-ALL. We report on a Ph-ALL patient who relapsed early after the first allogeneic HSCT, but achieved complete molecular remission with dasatinib alone. She remains in molecular remission 12 months after the second allogeneic HSCT. Dasatinib was generally well tolerated, but she developed myalgia, nausea and positive cytomegalovirus antigenemia. In addition, sudden-onset bloody diarrhea was observed 10 days after the second HSCT, which was possibly associated with the use of dasatinib in addition to the effect of the conditioning regimen and graft-versus-host disease. In conclusion, dasatinib is an effective agent for Ph-ALL with a poor prognosis, but may be associated with specific adverse events including opportunistic infection and gastrointestinal bleeding.

AB - Although allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), the prognosis of patients who relapse after allogeneic HSCT has been extremely poor. Dasatinib, a second-generation tyrosine kinase inhibitor, is a promising agent for the treatment of Ph-ALL. We report on a Ph-ALL patient who relapsed early after the first allogeneic HSCT, but achieved complete molecular remission with dasatinib alone. She remains in molecular remission 12 months after the second allogeneic HSCT. Dasatinib was generally well tolerated, but she developed myalgia, nausea and positive cytomegalovirus antigenemia. In addition, sudden-onset bloody diarrhea was observed 10 days after the second HSCT, which was possibly associated with the use of dasatinib in addition to the effect of the conditioning regimen and graft-versus-host disease. In conclusion, dasatinib is an effective agent for Ph-ALL with a poor prognosis, but may be associated with specific adverse events including opportunistic infection and gastrointestinal bleeding.

KW - Dasatinib

KW - Hematopoietic stem cell transplantation

KW - Philadelphia chromosome-positive acute lymphoblastic leukemia

UR - http://www.scopus.com/inward/record.url?scp=78549294155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549294155&partnerID=8YFLogxK

U2 - 10.1007/s12185-010-0678-6

DO - 10.1007/s12185-010-0678-6

M3 - Article

C2 - 20824399

AN - SCOPUS:78549294155

VL - 92

SP - 542

EP - 546

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -